CardieX Limited announced sales results for the first quarter September 2023. In the September quarter the Company has recorded unaudited revenue of $1.36 million (compared to $0.56 million in first quarter of fiscal year 2022), which is a year-on-year growth of 143% across Company's traditional business, with the sales and lease of Company's XCEL and Oscar 2 devices to pharmaceutical companies, research institutions, and specialist clinicians.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.066 AUD | 0.00% | +22.22% | -51.11% |
Apr. 02 | Australian Shares Inch Down As Market Assesses RBA Policy Meeting Minutes | MT |
Apr. 02 | Cardiex Marks Two Milestones Toward Wearable Biomarker Technology Commercialization; Shares Up 5% | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-51.11% | 11.79M | |
+11.18% | 227B | |
+15.22% | 198B | |
+19.19% | 142B | |
+30.89% | 111B | |
+1.56% | 64.16B | |
+18.48% | 54.1B | |
+5.12% | 51.41B | |
+10.53% | 45.32B | |
+5.98% | 37.32B |
- Stock Market
- Equities
- CDX Stock
- News CardieX Limited
- CardieX Limited Announces Sales Results for the First Quarter September 2023